GlaxoSmithKline plans to split into two businesses – one for Rx drugs and vaccines, and the other for OTC products – after forming a new joint venture with Pfizer’s consumer health division.

Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.